Acquisition Pending

Servier acquisition of Day One Biopharmaceuticals

US$2.5bn equity value

Announced 6 Mar 2026 · NASDAQ: DAWN · US$21.50 cash per share

Advisers

Day One Biopharmaceuticals

Target

Financial adviser
Legal adviser
Fairness opinion

Servier

Acquirer

Financial adviser
Legal adviser
Information Agent
Target
Day One Biopharmaceuticals
Acquirer
Servier
Target based in
United States
Buyer based in
France
Sector
Biotech
Tags
Biotech, Oncology, Pharma

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.